Robert Duncan Hite

Robert Duncan Hite

Auto-generated profile, based on publicly available information

Robert Duncan Hite

Division of Pulmonary, Critical Care and Sleep Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in JAMA
Verified
Journal Article
Open access
PDF file
AFAlpha Alsbury Fowler
Alpha Alsbury Fowler
JTJonathon D. Truwit
Jonathon D. Truwit
RHR. Duncan Hite
R. Duncan Hite
PMPeter E. Morris
Peter E. Morris
CDChristine DeWilde
Christine DeWilde
MHMatthew Halquist
Matthew Halquist
Acute respiratory distress syndrome (ARDS) is a common sepsis-associated organ injury and results in significant mortality1-4; for instance, the LUNG SAFE study reported 34% to 45% mortality.5 Despite advances in understanding mechanisms that lead to ARDS,6 disease-modifying strategies have not improved outcomes.7-12 Previous research found that vitamin C attenuates systemic inflammation, corrects sepsis-induced coagulopathy, and attenuates vascular injury.13-15 The CITRIS-ALI randomized trial examined whether high-dose vitamin C would reduce organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and ARDS.

27 December 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
TGTimothy D. Girard
Timothy D. Girard
MEMatthew C. Exline
Matthew C. Exline
SCShannon S. Carson
Shannon S. Carson
CHCatherine L. Hough
Catherine L. Hough
PRPeter Rock
Peter Rock
EEE. Wesley Ely
E. Wesley Ely
There are conflicting data on the effects of antipsychotic medications on delirium in patients in the intensive care unit (ICU). In a randomized, double-blind, placebo-controlled trial, we assigned patients with acute respiratory failure or shock and hypoactive or hyperactive delirium to receive intravenous boluses of haloperidol (maximum dose, 20 mg daily), ziprasidone (maximum dose, 40 mg daily), or placebo. The volume and dose of a trial drug or placebo was halved or doubled at 12-hour intervals on the basis of the presence or absence of delirium, as detected with the use of the Confusion Assessment Method for the ICU, and of side effects of the intervention. The primary end point was the number of days alive without delirium or coma during the 14-day intervention period. Secondary end points included 30-day and 90-day survival, time to freedom from mechanical ventilation, and time to ICU and hospital discharge. Safety end points included extrapyramidal symptoms and excessive sedation. Written informed consent was obtained from 1183 patients or their authorized representatives. Delirium developed in 566 patients (48%), of whom 89% had hypoactive delirium and 11% had hyperactive delirium. Of the 566 patients, 184 were randomly assigned to receive placebo, 192 to receive haloperidol, and 190 to receive ziprasidone. The median duration of exposure to a trial drug or placebo was 4 days (interquartile range, 3 to 7). The median number of days alive without delirium or coma was 8.5 (95% confidence interval [CI], 5.6 to 9.9) in the placebo group, 7.9 (95% CI, 4.4 to 9.6) in the haloperidol group, and 8.7 (95% CI, 5.9 to 10.0) in the ziprasidone group (P=0.26 for overall effect across trial groups). The use of haloperidol or ziprasidone, as compared with placebo, had no significant effect on the primary end point (odds ratios, 0.88 [95% CI, 0.64 to 1.21] and 1.04 [95% CI, 0.73 to 1.48], respectively). There were no significant between-group differences with respect to the secondary end points or the frequency of extrapyramidal symptoms. The use of haloperidol or ziprasidone, as compared with placebo, in patients with acute respiratory failure or shock and hypoactive or hyperactive delirium in the ICU did not significantly alter the duration of delirium. (Funded by the National Institutes of Health and the VA Geriatric Research Education and Clinical Center; MIND-USA ClinicalTrials.gov number, NCT01211522.)

5 June 2014 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
NNNational Heart, Lung, and Blood Institute ARDS Clinical Trials Network
National Heart, Lung, and Blood Institute ARDS Clinical Trials Network
JTJonathon D Truwit
Jonathon D Truwit
GBGordon R Bernard
Gordon R Bernard
JSJay Steingrub
Jay Steingrub
MMMichael A Matthay
Michael A Matthay
BTB Taylor Thompson
B Taylor Thompson
In the acute respiratory distress syndrome (ARDS), inflammation in the lungs and other organs can cause life-threatening organ failure. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) can modulate inflammatory responses. Previous observational studies suggested that statins improved clinical outcomes in patients with sepsis. We hypothesized that rosuvastatin therapy would improve clinical outcomes in critically ill patients with sepsis-associated ARDS. We conducted a multicenter trial in which patients with sepsis-associated ARDS were randomly assigned to receive either enteral rosuvastatin or placebo in a double-blind manner. The primary outcome was mortality before hospital discharge home or until study day 60 if the patient was still in a health care facility. Secondary outcomes included the number of ventilator-free days (days that patients were alive and breathing spontaneously) to day 28 and organ-failure–free days to day 14. The study was stopped because of futility after 745 of an estimated 1000 patients had been enrolled. There was no significant difference between study groups in 60-day in-hospital mortality (28.5% with rosuvastatin and 24.9% with placebo, P=0.21) or in mean (±SD) ventilator-free days (15.1±10.8 with rosuvastatin and 15.1±11.0 with placebo, P=0.96). The groups were well matched with respect to demographic and key physiological variables. Rosuvastatin therapy, as compared with placebo, was associated with fewer days free of renal failure to day 14 (10.1±5.3 vs. 11.0±4.7, P=0.01) and fewer days free of hepatic failure to day 14 (10.8±5.0 vs. 11.8±4.3, P=0.003). Rosuvastatin was not associated with an increased incidence of serum creatine kinase levels that were more than 10 times the upper limit of the normal range. Rosuvastatin therapy did not improve clinical outcomes in patients with sepsis-associated ARDS and may have contributed to hepatic and renal organ dysfunction. (Funded by the National Heart, Lung, and Blood Institute and the Investigator-Sponsored Study Program of AstraZeneca; ClinicalTrials.gov number, NCT00979121.)

28 June 2016 in JAMA
Verified
Journal Article
Open access
PDF file
PMPeter E. Morris
Peter E. Morris
MBMichael J. Berry
Michael J. Berry
DFD. Clark Files
D. Clark Files
JTJ. Clifton Thompson
J. Clifton Thompson
JHJordan Hauser
Jordan Hauser
MYMichael P. Young
Michael P. Young
Acute respiratory failure is associated with high mortality and prolonged morbidity, with impaired physical function for many survivors. Interventions directed at attenuating the profound muscle wasting in patients with acute respiratory failure are patient-centered.1 Such therapies designed to improve patient-reported weakness and impaired physical function could reduce recovery time in patients with acute respiratory failure. As well, such interventions could potentially improve long-term health-related quality of life, which for this population is commonly below normal following hospital discharge.2-4 Reports have suggested that a rehabilitation program, delivered by an intensive care unit (ICU) rehabilitation team, may be associated with reduced length of stay (LOS) and improved physical function, although findings to the contrary exist as well.5-11 This randomized clinical trial was designed to test the hypothesis that early delivery of a standardized, multifaceted ICU and hospital rehabilitation program would decrease hospital LOS and improve physical function for patients with acute respiratory failure.

1 January 2016 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
RSRachel G. Scheraga
Rachel G. Scheraga
SASusamma Abraham
Susamma Abraham
KNKathryn A Niese
Kathryn A Niese
BSBrian D. Southern
Brian D. Southern
LGLisa M. Grove
Lisa M. Grove
MOMitchell A Olman
Mitchell A Olman
Macrophage phagocytosis of particles and pathogens is an essential aspect of innate host defense. Phagocytic function requires cytoskeletal rearrangements that depend on the interaction between macrophage surface receptors, particulates/pathogens, and the extracellular matrix. In the present study we determine the role of a mechanosensitive ion channel, transient receptor potential vanilloid 4 (TRPV4), in integrating the LPS and matrix stiffness signals to control macrophage phenotypic change for host defense and resolution from lung injury. We demonstrate that active TRPV4 mediates LPS-stimulated murine macrophage phagocytosis of nonopsonized particles (Escherichia coli) in vitro and opsonized particles (IgG-coated latex beads) in vitro and in vivo in intact mice. Intriguingly, matrix stiffness in the range seen in inflamed or fibrotic lung is required to sensitize the TRPV4 channel to mediate the LPS-induced increment in macrophage phagocytosis. Furthermore, TRPV4 is required for the LPS induction of anti-inflammatory/proresolution cytokines. These findings suggest that signaling through TRPV4, triggered by changes in extracellular matrix stiffness, cooperates with LPS-induced signals to mediate macrophage phagocytic function and lung injury resolution. These mechanisms are likely to be important in regulating macrophage function in the context of pulmonary infection and fibrosis.

1 February 2015 in Critical Care Medicine
Verified
Journal Article
Closed access
CGColin K. Grissom
Colin K. Grissom
EHEliotte L. Hirshberg
Eliotte L. Hirshberg
JDJustin B. Dickerson
Justin B. Dickerson
SBSamuel M. Brown
Samuel M. Brown
MLMichael J. Lanspa
Michael J. Lanspa
AMAlan H. Morris
Alan H. Morris
Objectives: In the Fluid and Catheter Treatment Trial (FACTT) of the National Institutes of Health Acute Respiratory Distress Syndrome Network, a conservative fluid protocol (FACTT Conservative) resulted in a lower cumulative fluid balance and better outcomes than a liberal fluid protocol (FACTT Liberal). Subsequent Acute Respiratory Distress Syndrome Network studies used a simplified conservative fluid protocol (FACTT Lite). The objective of this study was to compare the performance of FACTT Lite, FACTT Conservative, and FACTT Liberal protocols. Design: Retrospective comparison of FACTT Lite, FACTT Conservative, and FACTT Liberal. Primary outcome was cumulative fluid balance over 7 days. Secondary outcomes were 60-day adjusted mortality and ventilator-free days through day 28. Safety outcomes were prevalence of acute kidney injury and new shock. Setting: ICUs of Acute Respiratory Distress Syndrome Network participating hospitals. Patients: Five hundred three subjects managed with FACTT Conservative, 497 subjects managed with FACTT Liberal, and 1,124 subjects managed with FACTT Lite. Interventions: Fluid management by protocol. Measurements and Main Results: Cumulative fluid balance was 1,918 ± 323 mL in FACTT Lite, –136 ± 491 mL in FACTT Conservative, and 6,992 ± 502 mL in FACTT Liberal (p < 0.001). Mortality was not different between groups (24% in FACTT Lite, 25% in FACTT Conservative and Liberal, p = 0.84). Ventilator-free days in FACTT Lite (14.9 ± 0.3) were equivalent to FACTT Conservative (14.6 ± 0.5) (p = 0.61) and greater than in FACTT Liberal (12.1 ± 0.5, p < 0.001 vs Lite). Acute kidney injury prevalence was 58% in FACTT Lite and 57% in FACTT Conservative (p = 0.72). Prevalence of new shock in FACTT Lite (9%) was lower than in FACTT Conservative (13%) (p = 0.007 vs Lite) and similar to FACTT Liberal (11%) (p = 0.18 vs Lite). Conclusions: FACTT Lite had a greater cumulative fluid balance than FACTT Conservative but had equivalent clinical and safety outcomes. FACTT Lite is an alternative to FACTT Conservative for fluid management in Acute Respiratory Distress Syndrome.